Acidic and basic fibroblast growth factors (FGFs) are members of a family of multifunctional polypeptide growth factors that stimulate proliferation of cells of mesenchymal, epithelial and neuroectodermal origin. Like other growth factors, FGFs act by binding and activating specific cell surface receptors. These include the Flg receptor or FGFR-1, the Bek receptor (or FGFR-2), FGFR-3, FGFR-4, FGFR-5 and FGFR-6. These receptors usually contain an extracellular ligand-binding region containing three immunoglobulin-like domains, a transmembrane domain and a cytoplasmic tyrosine kinase domain. The gene encoding human Bek (also designated K-sam) maps to chromosome 10q26.13 and is alternatively spliced to produce several isoforms. Heterogeneous mutations in Bek are associated with a range of craniosynostosis syndromes including Pfeiffer syndrome, Crouzon syndrome, Jackson-Weiss syndrome and Apert syndrome..
Background References
1. Ramsey MR et al. FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma. J Clin Invest 123:3525-38 (2013).
2. Huang Y et al. Twist1- and twist2-haploinsufficiency results in reduced bone formation. PLoS One 9:e99331 (2014).
Western blot analysis of FGFR2 on different lysates with Rabbit anti-FGFR2 antibody (HA724655) at 1/1,000 dilution.
Lane 1: Saos-2 (Human osteosarcoma cell) cell lysate
Lane 2: SW620 (Human colon cancer cell) cell lysate
Lane 3: HT-29 (Human colorectal adenocarcinoma cell) cell lysate
Lane 4: HCT 116 (Human colon cancer cell) cell lysate
Lane 5: NIH/3T3 (Mouse fibroblast) cell lysate
Lysates/proteins at 15 µg/Lane.
Exposure time: 2 seconds; ECL: K1801
FGFR2/KGFR/K-sam recognizes endogenous levels of total FGFR2 protein and a C-terminal truncated form K-sam (PMID: 17505008).
Negative control: SW620 (PMID: 24968263)
Blocking: 5% NFDM/TBST, 1 hour at room temperature
Primary antibody: HA724655, 1/1,000 in primary antibody dilution buffer (K1803), overnight at 4 °C
Secondary antibody: Goat anti-Rabbit IgG-HRP (HA1001), 1/50,000 in 5% NFDM/TBST, 1 hour at room temperature
Predicted band size: 92 kDa
Observed band size: 145 kDa
☑ Cell treatment (CT)
Western blot analysis of FGFR2 on different lysates with Rabbit anti-FGFR2 antibody (HA724655) at 1/5,000 dilution.
Lane 1: Saos-2 (Human osteosarcoma cell) cell lysate
Lane 2: Saos-2 treated with Deglycosylation cell lysate
Blocking: 5% NFDM/TBST, 1 hour at room temperature
Primary antibody: HA724655, 1/5,000 in primary antibody dilution buffer (K1803), overnight at 4 °C
Secondary antibody: Goat anti-Rabbit IgG-HRP (HA1001), 1/50,000 in 5% NFDM/TBST, 1 hour at room temperature
Predicted band size: 92 kDa
Observed band size: 145 kDa
☑ Relative expression (RE)
Application: Flow Cytometry
Species: Human Sample: SW620 (Human colon cancer cell) (Left, Negative) / Saos-2 (Human osteosarcoma cell) (Right)
Blocking: 1% BSA + 10% normal goat serum + human FcR (Miltenyi Biotec), 15 minutes at room temperature. Antibody dilution buffer: 1x PBS.
Primary antibody: HA724655 (1/1,000, Red) compared with Rabbit IgG Isotype Control (HA722127, Green), 15 minutes at room temperature. Secondary antibody: Goat Anti-Rabbit IgG (iFluor™ 488, HA1121), 15 minutes at room temperature.
Negative control: SW620 (PMID: 24968263).
Immunoprecipitation (IP)
FGFR2 was immunoprecipitated in 0.2 mg Saos-2 (Human osteosarcoma cell) cell lysate with HA724655 at 2 µg/10 µl beads. Western blot was performed from the immunoprecipitate using HA724655 at 1/5,000 dilution. Anti-Rabbit IgG for IP, AlpSdAbs® VHH(HRP) (025-100-005) at 1/5,000 dilution was used for 1 hour at room temperature.
Lane 1: Saos-2 cell lysate (input) Lane 2: HA724655 IP in Saos-2 cell lysate Lane 3: Rabbit IgG instead of HA724655 in Saos-2 cell lysate
Exposure time: 3 minutes Blocking: 5% NFDM/TBST, 1 hour at room temperature
Primary dilution: HA724655, 1/5,000 in primary antibody dilution buffer (K1803), 2 hours at room temperature
Predicted band size: 92 kDa Observed band size: 145 kDa
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"